Logistic regression model for factors associated with microbiologically documented bacteremia during postremission treatment
| . | . | . | Multivariate analysis . | ||
|---|---|---|---|---|---|
| . | n . | No. of events . | aOR . | 95% CI . | P . |
| HDAC regimen | |||||
| HDAC-123 | 91 | 33 | 1 | — | — |
| HDAC-135 | 129 | 62 | 1.28 | 0.69-2.38 | .43 |
| Prophylactic G-CSF* | |||||
| Standard G-CSF | 49 | 27 | 1 | — | — |
| Pegylated G-CSF | 171 | 68 | 0.46 | 0.23-0.90 | .02 |
| No. of HDAC cycles | |||||
| 1 | 27 | 6 | 1 | — | — |
| 2 | 68 | 27 | 2.71 | 0.94-7.79 | .06 |
| 3 | 125 | 62 | 4.11 | 1.50-11.21 | <.01 |
| . | . | . | Multivariate analysis . | ||
|---|---|---|---|---|---|
| . | n . | No. of events . | aOR . | 95% CI . | P . |
| HDAC regimen | |||||
| HDAC-123 | 91 | 33 | 1 | — | — |
| HDAC-135 | 129 | 62 | 1.28 | 0.69-2.38 | .43 |
| Prophylactic G-CSF* | |||||
| Standard G-CSF | 49 | 27 | 1 | — | — |
| Pegylated G-CSF | 171 | 68 | 0.46 | 0.23-0.90 | .02 |
| No. of HDAC cycles | |||||
| 1 | 27 | 6 | 1 | — | — |
| 2 | 68 | 27 | 2.71 | 0.94-7.79 | .06 |
| 3 | 125 | 62 | 4.11 | 1.50-11.21 | <.01 |
*Prophylactic G-CSF during first cycle of HDAC.